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biosynthesis  of  ceramides,  complex  lipids  containing  a 





bation of  the distribution of  ceramide molecular  species 
promotes lipotoxicity in cultured cardiomyocytes (15). In 
the myocardium of T2D animal models and in models of 
Abstract Cardiac dysfunction in T2D is associated with ex-
cessive FA uptake, oxidation, and generation of toxic lipid 
species by the heart. It is not known whether decreasing lipid 
delivery to the heart can effect improvement in cardiac func-
tion in humans with T2D. Thus, our objective was to test the 
hypothesis that lowering lipid delivery to the heart would re-
sult in evidence of decreased “lipotoxicity,” improved car-
diac function, and salutary effects on plasma biomarkers of 
cardiovascular risk. Thus, we performed a double-blind ran-
domized placebo-controlled parallel design study of the ef-
fects of 12 weeks of fenofibrate-induced lipid lowering on 
cardiac function, inflammation, and oxidation biomarkers, 
and on the ratio of two plasma ceramides, Cer d18:1 (4E) 
(1OH, 3OH)/24:0 and Cer d18:1 (4E) (1OH, 3OH)/16:0 
(i.e., “C24:0/C16:0”), which is associated with decreased 
risk of cardiac dysfunction and heart failure. Fenofibrate 
lowered plasma TG and cholesterol but did not improve 
heart systolic or diastolic function. Fenofibrate treatment 
lowered the plasma C24:0/C16:0 ceramide ratio and min-
imally altered oxidative stress markers but did not alter 
measures of inflammation. Overall, plasma TG lowering cor-
related with improvement of cardiac relaxation (diastolic 
function) as measured by tissue Doppler-derived parameter 
e′. Moreover, lowering the plasma C24:0/C16:0 ceramide ra-
tio was correlated with worse diastolic function. These find-
ings indicate that fenofibrate treatment per se is not sufficient 
to effect changes in cardiac function; however, decreases in 
plasma TG may be linked to improved diastolic function.  
In contrast, decreases in plasma C24:0/C16:0 are linked with 
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Abnormalities  of  lipid metabolism  in  diabetes  have  also 
been  associated  with  LV  dysfunction  in  humans.  In  the 
Multiethnic Study of Atherosclerosis,  incident heart failure 
in participants with diabetes was increased and was highest in 
diabetic  subjects with hypertriglyceridemia  (25).  Increased 














































tion,  evidence  of  CHD  on  screening  stress  echocardiography, 
heart failure, hemoglobin A1c (HbA1c) >10%, recreational drug 
or  severe alcohol use, history of  liver disease,  renal dysfunction 
(creatinine >1.5 mg/dl), use of anticoagulants, presence of para-
doxical septal motion or more than mild valvular heart disease, or 

















Study  subjects  recorded  blood  glucose  concentrations  daily, 
which were  reviewed at monthly  visits,  and kept an acute event 
log, since TGs are acute phase reactants.
Plasma/serum/urine measurements other than ceramides
Plasma insulin was measured using a sandwich electrochemilu-
minescence immunoassay and a Roche Cobas c601 analyzer, Ba-
sel,  Switzerland).  Plasma  glucose  levels  were  measured  using 
enzymatic colorimetric assays on the Roche c501 analyzer (Roche 
Diagnostics, North America). After a 12 h fast, HDL, TG, and total 
cholesterol  levels  were measured  from  plasma  using  enzymatic 
colorimetric assays run on the Roche c501 analyzer. HbA1c was 





metric  kit,  and  systemic  inflammatory markers  [high  sensitivity 
C-reactive protein (hsCRP), TNF-, and interleukin 6 (IL-6) were 
quantified using reagent kits from Roche Diagnostics]. Markers of 








pared  the  concentration-response  of  the  analyte  in  a  surrogate 
matrix (e.g., 5% BSA) to that of plasma samples. To determine 
recovery, the plasma or surrogate matrix was spiked with differing 
amounts  of  d4-C22:0  and  d4-C24:0,  extracted with  chloroform/
methanol and analyzed as above. Differences in matrix effects and 
extraction  recoveries  were  compensated  by  internal  standards. 
Details of  the metabolomic analytical methods used were previ-
ously reported by our group (38).
Body composition and liver fat measurement
Subjects underwent baseline anthropomorphic and metabolic 
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determination of body composition (iDXA; GE Healthcare, Madi-

























tertiary  endpoints.  Two-sample  t-tests  were  used  for  comparing 
continuous  variables between groups  and Chi-square  tests were 
used  for  categorical  variables.  Satterthwaite  analysis  was  per-
formed if variables had unequal variances. For comparison of the 
proportion of subjects taking certain medications, two-sample Z 
test  for  proportions  was  used. One  sample  t-tests  were  used  to 
compare means of the deltas of the endpoints. ANCOVA was used 
















The CONSORT  diagram  (Fig. 1)  outlines  the  recruit-


























ences  in age,  sex,  racial  composition,  anthropomorphic 
and metabolic characteristics, oxidative stress markers, or 




line, but LV mass  and volume and  systolic  (FS,  ejection 
fraction, global longitudinal strain, tissue Doppler s′ aver-
age)  and  diastolic  (e′  average,  E/e′  septal)  functional 
measurements were not significantly different (Table 1). 









Effects of 12 weeks of fenofibrate/placebo intervention 
on anthropomorphic, metabolic, hemodynamic, and 



















(propanoyl)-lysine  between  the  fenofibrate  and  placebo 
groups,  with  the  fenofibrate  group  having  a  greater  
decrease in the concentration of this marker (Table 4). 
TABLE  1.  Baseline characteristics
Normal Range Placebo (n = 34) Fenofibrate (n = 31) P
Age (years) NA 54.4 ± 8.6 54.5 ± 8.6 0.96
Sex (percent women) NA 64.7 74.2 0.41
Race (percent white) NA 76.5 77.4 0.62




Liver fat (%) 5.56c 13.76 ± 7.93 15.96 ± 10.08 0.38
Total cholesterol (mmol/l) <3.8d 4.43 ± 1.06 4.69 ± 0.85 0.27
LDL cholesterol (mmol/l) <2.6d 2.30 ± 0.98 2.56 ± 0.70 0.22
HDL cholesterol (mmol/l) NA 1.14 ± 0.32 1.24 ± 0.34 0.24
TGs (mmol/l) NA 2.30 ± 1.00 2.01 ± 1.34 0.32
Fasting FFAs (mmol/l) NA 0.597 ± 0.233 0.622 ± 0.219 0.66
Fasting insulin (pmol/l) NA 165.44 ± 124.19 206.86 ± 204.58 0.33
Fasting glucose (mmol/l) <5.5e 7.54 ± 2.49 7.40 ± 1.59 0.79





Glycated albumin (%) NA 15.65 ± 3.82 16.21 ± 3.25 0.53
Ceramide 24:0 (g/ml) 0.735–3.50f 2.48 ± 0.70 2.35 ± 0.61 0.46
Ceramide 16:0 (g/ml) 0.0612–0.270f 0.203 ± 0.043 0.214 ± 0.052 0.36
Ceramide 24:0/C16:0 6.43–25.0f 12.35 ± 3.04 11.21 ± 2.38 0.10
hsCRP (mg/l) ≤3a 4.08 ± 2.80 6.58 ± 5.18g 0.02
TNF- (pg/ml) NA 1.81 ± 0.66 1.79 ± 0.51 0.88
IL-6 NA 4.39 ± 6.31 4.13 ± 1.88 0.82
Plasma N-(hexanoyl)-lysine (ng/mg) NA 0.16 ± 0.04 0.16 ± 0.06 0.64
Plasma N-(propanoyl)-lysine (ng/mg) NA 3.02 ± 0.67 3.18 ± 0.63 0.30
Urinary N-(hexanoyl)-lysine (ng/mg) NA 45.24 ± 23.76 45.80 ± 25.07 0.93




























Specific lipids were significantly affected by fenofibrate 








fenofibrate  had  significantly  decreased  cholesterol  (P  = 








integrated  lipid  exposure  of  nonadipose  tissues  over  the 
course of the 12 week treatment, we used proton MRS to 
quantify hepatic TG noninvasively. Liver TG was chosen as 
an  endpoint  rather  than  cardiac TG because  the  higher 



























Normal Range Placebo (n = 34) Fenofibrate (n = 31) P
Heart rate (bpm) 60–100a 71.9 ± 8.9 73.6 ± 10.0 0.47
Systolic blood pressure (mmHg) <120a 127.2 ± 10.7 125.9 ± 11.9 0.65
Diastolic blood pressure (mmHg) <80a 78.6 ± 7.5 75.3 ± 10.1 0.14
Mean arterial pressure (mmHg) <93a 95.9 ± 7.9 94.3 ± 7.9 0.40
LV mass (g) Men, 96–200;b women, 66–150b 145.9 ± 33.4 153.3 ± 39.2 0.42
LV end-diastolic volume (ml) Men, 106 ± 22;b women, 76 ± 15b 88.7 ± 18.6 86.9 ± 21.0 0.72
Relative wall thickness Men, 0.24–0.42;b women, 0.22–0.42b 0.43 ± 0.08 0.48 ± 0.10 0.04
Ejection fraction (%) Men, 62 ± 5;b women, 64 ± 5b 68 ± 5 68 ± 6 0.96
FS (%) 18b 38 ± 6 39 ± 7 0.61
Global longitudinal strain (%)c  21.2 ± 2.4b 17.81 ± 2.1 17.8 ± 2.56 0.98
s′ average (cm/s) NA 8.10 ± 1.73 7.82 ± 1.27 0.46
e′ average (cm/s) NA 7.99 ± 1.78 8.30 ± 1.70 0.48










Statin 16 16 0.71
Insulin 7 6 0.90
Metformin 25 25 0.50
Thiazolidinedione 1 0 0.34
Sulfonylurea 10 8 0.75
DPP-4 inhibitor 3 4 0.60
SGLT-2 inhibitor 5 4 0.83
GLP-1 agonist 6 6 0.86
Calcium channel blocker 7 7 0.84
Beta-blocker 3 5 0.37
ACE-inhibitor/ARB antagonist 19 17 0.94
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Diastolic relaxation was inversely related to change in 
plasma TG and directly related to change in plasma 
C24:0/C16:0 ceramide ratio
As shown in Fig. 3 and Table 4, there were no significant 

















the  effects  of decreasing plasma TG on  cardiac  function 
and biomarkers of metabolic stress in patients with T2D. As 










genesis  of  lipotoxicity.  Fenofibrate  treatment  did  not 
change liver steatosis or markers of inflammation, and only 






and  because  a  lower  plasma  ceramide  ratio  is  associated 
with lower LV ejection fraction and diminished global cir-
cumferential  strain (46),  this finding  is unanticipated, as 
TG lowering would be expected to improve cardiovascular 
risk (31). On the other hand, consistent with the hypothe-
sis  that  decreasing C24:0/C16:0  ceramide  ratios  portend 




diac  function,  regardless  of  treatment  group,  correlates 





















in  the  ACCORD  lipid  study,  fenofibrate  did  not  reduce 
CHD  or  heart  failure  events  in  patients  with  T2D  (30), 
whereas the FIELD study showed that fenofibrate reduced 
cardiovascular  disease  events  in  women  with  T2D  (48). 
These and other studies have focused on endpoints of hos-
pitalization for CHD or heart failure and/or cardiovascular 
deaths, whereas our  study  focused on LV  function  as  an 
outcome.
Fig. 2.  Lipid alterations after placebo or fenofibrate intervention. 
A:  Serum  TGs  decreased more  after  fenofibrate  treatment  com-
pared with after placebo (*P < 0.05). B: No significant change in 
plasma FFAs. C: Lack of significant change in liver fat percentage 
between  the  fenofibrate and placebo groups. D: The ratio of  the 
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Ceramides are complex lipids with pleiotropic biological 
effects (49). Depending on fatty acyl chain lengths, these 
hydrophobic  molecules  differentially  affect  membrane 
structure and function as well as number of signaling path-
ways in cells (14, 49). Although the effects of each ceramide 
species  is  not  completely  understood,  several  lines  of  re-
search now point to C16:0 as being involved in mitochon-









 BMI (kg/m2) 0.21 ± 0.93 1.46 ± 7.71 0.24
 Liver fat (%) 0.27 ± 3.40 1.71 ± 4.54 0.16
 Total cholesterol(mmol/l) 0.21 ± 0.69 0.28 ± 0.62 0.004
 LDL cholesterol (mmol/l) 0.12 ± 0.61 0.13 ± 0.53 0.08
 HDL cholesterol (mmol/l) 0.02 ± 0.17 0.05 ± 0.22 0.60
 TGs (mmol/l) 0.01 ± 0.67 0.31 ± 0.59 0.048
 Fasting FFAs (mmol/l) 0.01 ± 0.25 0.10 ± 0.25 0.14
 Fasting insulin (pmol/l) 5.65 ± 65.37 10.18 ± 67.71 0.78
 Fasting glucose (mmol/l) 0.11 ± 2.25 0.63 ± 1.82 0.31
 Glycated albumin (%) 0.20 ± 1.63 0.43 ± 2.33 0.66
 C24:0 ceramide 0.045 ± 0.64 0.41 ± 0.36 0.00073
 C16:0 ceramide 0.0029 ± 0.028 0.0061 ± 0.27 0.19
 C24:0/C16:0 ceramide ratio 0.04 ± 2.44 1.6 ± 1.66 0.0036
 hsCRP (mg/l) 0.03 ± 2.27 1.10 ± 2.94 0.11
 TNF- (pg/ml) 0.04 ± 0.68 0.32 ± 0.97 0.09
 IL-6 (pg/ml) 1.01 ± 5.97 0.65 ± 3.52 0.17
 Plasma N-(hexanoyl)-lysine (ng/ml) 0.053 ± 0.035 0.059 ± 0.055 0.65
 Plasma N-(propanoyl)-lysine (ng/ml) 0.737 ± 0.685 1.124 ± 0.720 0.03
 Urinary N-(hexanoyl)-lysine (ng/ml) 7.10 ± 24.66 15.85 ± 23.85 0.65
 Urinary N-(propanoyl)-lysine (ng/ml) 44.73 ± 68.05 40.38 ± 76.31 0.81
 Heart rate (bpm) 1.59 ± 8.86 1.58 ± 10.02 1.000
 Mean arterial pressure (mmHg) 0.3 ± 8.3 3.4 ± 8.8 0.15
 LV end-diastolic volume (ml) 1.71 ± 10.87 0.52 ± 11.59 0.43
 Relative wall thickness 0.02 ± 0.05 0.02 ± 0.04 0.74
 Ejection fraction (%) 1.4 ± 4.8 3.1 ± 5.2 0.19
 FS (%) 0.030 ± 0.083 0.025 ± 0.090 0.80
 Global longitudinal strain (%)a 0.26 ± 2.02 0.23 ± 1.76 0.96
 s′ average (cm/s) 0.16 ± 1.81 0.68 ± 1.04 0.17
 e′ average (cm/s) 0.55 ± 1.58 0.02 ± 1.35 0.13























of  incident CHD, heart  failure, and all-cause mortality  in 
meta-analyses  (32).  It  is  not  known  whether  the  plasma 
C24:0/C16:0 ceramide  ratio  is  a  reflection of  changes  in 
tissue  lipid  homeostasis  or  whether  these  lipids  function 
directly  in pathogenesis of cardiovascular disease. Fenofi-
brate is thought to decrease plasma TGs through activation 
of  PPARs  (51).  Precisely  how  PPAR  agonism  affects  the 
complex metabolic pathways that regulate levels of specific 
ceramide molecular species or the C24:0/C16:0 ratio is not 
known. Here, we provide evidence  that  fenofibrate  treat-











be  required  to more  fully  evaluate  the  effects  of  fenofi-
brate on the ceramide ratio and its associations with car-
diovascular risk.
Other  factors  that mitigate or amplify  the  lipotoxic re-
sponse (steatosis, oxidative stress, and inflammation) were 











of oxidative  stress were unchanged. Furthermore,  the  in-
flammatory markers examined were unchanged by fenofi-
brate therapy. These findings fit into a mixed picture of the 
effects of  this drug on oxidative  stress  and  inflammation 
markers in the literature that may reflect the limitations of 














Although  fenofibrate  treatment  (n  =  31)  versus pla-
cebo (n = 34) did not alter the primary cardiac function 










sis.  The  finding  that  fenofibrate  treatment  was  associ-
ated with  a decrease  in plasma ceramide C24:0/C16:0 
ratio  does  not  automatically  signify  that  fenofibrate  is 
associated  with  worse  cardiac  outcomes;  for  it  is  not 
clear  yet  if  low C24:0/C16:0  ceramide  ratio  is  causally 
linked  or  simply  associated with worse  outcomes.  Fur-










tutes  of  Health  and  Washington  University  School  of 
Medicine. This trial was registered at clinicaltrials.gov as 
NCT01752842.
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